<DOC>
	<DOCNO>NCT00047645</DOCNO>
	<brief_summary>Study GIPF-001 phase 3 study design determine safety efficacy IFN-g 1b administer subcutaneous injection ; compare placebo patient IPF unresponsive steroid . 330 patient enrol assigned either IFN-g 1b group placebo group .</brief_summary>
	<brief_title>A Study Safety Efficacy Interferon-Gamma 1b Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Male Female , 2079 year old</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>lung</keyword>
	<keyword>IPF</keyword>
</DOC>